Ethicon seals Omrix deal
This article was originally published in The Gray Sheet
Executive Summary
Wound management division of J&J unit gains exclusive North American marketing and distribution rights for Crosseal fibrin sealant from Belgian firm Omrix Biopharmaceuticals, adding to an exclusive European pact from June 2003. The first non-bovine sealant to launch in the U.S., Crosseal originally was cleared via biologics license application in March 2003 for use as an adjunct to hemostasis in liver surgery patients. Ethicon notes the device has a triple lumen delivery mechanism that does not mix the human thrombin and biological active component until they reach the tip - a feature that may prevent clogging seen in other sealants. Baxter's Tisseel uses aprotinin, a protein derived from cow lungs, and is Crosseal's chief competitor (1"The Gray Sheet" July 28, 2003, p. 16)...
You may also be interested in...
Non-Bovine Fibrin Sealant Launches In U.S.; Red Cross To Distribute Crosseal
American Red Cross Plasma Services' three U.S. distributors will ship Omrix Biopharmaceuticals' Crosseal fibrin sealant to liver surgeons throughout the summer
Prestige Expands UK Eye Care Range In Response To Consumer Demand
A “great consumer response” to TheraTears in the UK leads Prestige Consumer Healthcare to add TheraTears 5-in-1 Irritation and Redness eye drops to the range.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.